Skip to content
Homepage
Category:
Business
Posted Date:
June 5, 2026
Hyperbaric Chamber Nashville: How HBOT, IV Therapy, and EBO2 Support Personalized Recovery Protocols
Written By: EIN Presswire
June 5, 2026
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion, Inc.
June 5, 2026
DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
Edelson Lechtzin LLP
June 5, 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics, Inc.
June 5, 2026
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism
Oban BioPharma, Inc.
June 5, 2026
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices
June 5, 2026
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
NOVO NORDISK INC.
June 5, 2026
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
AMERICAN DIABETES ASSOCIATION
June 5, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
Ambrosia Biosciences
June 5, 2026
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
Precision Diabetes, Inc.
June 5, 2026
Prev
1
…
2,132
2,133
2,134
